Klotho Neurosciences, Inc. (KLTO)
NASDAQ: KLTO · Real-Time Price · USD
0.2250
-0.0370 (-14.12%)
At close: Mar 28, 2025, 4:00 PM
0.2414
+0.0164 (7.29%)
After-hours: Mar 28, 2025, 7:05 PM EDT
Company Description
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer’s disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
The company is based in Omaha, Nebraska.
Klotho Neurosciences, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Joseph Sinkule |
Contact Details
Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States | |
| Phone | 833 931 6330 |
| Website | klothoneuro.com |
Stock Details
| Ticker Symbol | KLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907223 |
| ISIN Number | US49876K1034 |
| Employer ID | 86-2727441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Sinkule Pharm.D. | Founder, Chief Executive Officer, Chairman of the Board and Secretary |
| Jeffrey LeBlanc | Chief Financial Officer |
| Peter J. Moriarty | Chief Operating Officer and Chief Business Officer |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Officer and Consultant |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor and Director |
| Dr. Bradford A. Navia M.D., Ph.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 424B3 | Prospectus |
| Feb 10, 2025 | EFFECT | Notice of Effectiveness |
| Feb 6, 2025 | UPLOAD | Filing |
| Jan 30, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jan 24, 2025 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 10-Q | Quarterly Report |